Compare Stocks: NERV, HELP, GLAS, and ACHV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49	$6.93	$2.62 ▼ $8.64	$873.62M	2.25	1.44 million shs	874,073 shs
GLAS Glass House Brands	$8.89 +0.1%	$10.24	$5.15 ▼ $13.93	$833.88M	N/A	463,798 shs	482,193 shs
HELP Cybin	$12.22	$9.44	$3.76 ▼ $14.35	$923.95M	0.63	1.66 million shs	1.02 million shs
NERV Minerva Neurosciences	$4.43	$4.52	$1.93 ▼ $12.46	$211.53M	-0.08	243,820 shs	78,435 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	+4.81%	+27.67%	+54.93%	+200.00%
GLAS Glass House Brands	0.00%	-10.38%	-11.92%	+888,999,900.00%	+888,999,900.00%
HELP Cybin	0.00%	+0.33%	+5.25%	+204.74%	+1,221,999,900.00%
NERV Minerva Neurosciences	0.00%	-8.47%	+3.75%	-4.32%	+88.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49	$6.93	$2.62 ▼ $8.64	$873.62M	2.25	1.44 million shs	874,073 shs
GLAS Glass House Brands	$8.89 +0.1%	$10.24	$5.15 ▼ $13.93	$833.88M	N/A	463,798 shs	482,193 shs
HELP Cybin	$12.22	$9.44	$3.76 ▼ $14.35	$923.95M	0.63	1.66 million shs	1.02 million shs
NERV Minerva Neurosciences	$4.43	$4.52	$1.93 ▼ $12.46	$211.53M	-0.08	243,820 shs	78,435 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	+4.81%	+27.67%	+54.93%	+200.00%
GLAS Glass House Brands	0.00%	-10.38%	-11.92%	+888,999,900.00%	+888,999,900.00%
HELP Cybin	0.00%	+0.33%	+5.25%	+204.74%	+1,221,999,900.00%
NERV Minerva Neurosciences	0.00%	-8.47%	+3.75%	-4.32%	+88.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	76.68% Upside
GLAS Glass House Brands	2.00	Hold	$16.00	79.98% Upside
HELP Cybin	3.00	Buy	$48.60	297.71% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	133.26% Upside

Current Analyst Ratings Breakdown

Latest NERV, HELP, GLAS, and ACHV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	GLAS Glass House Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2026	GLAS Glass House Brands	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/27/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$16.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
GLAS Glass House Brands	N/A	N/A	N/A	44.45	N/A	N/A	N/A	N/A	N/A
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)

Latest NERV, HELP, GLAS, and ACHV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
GLAS Glass House Brands	N/A	N/A	N/A
HELP Cybin	N/A	10.97	10.97
NERV Minerva Neurosciences	N/A	20.15	20.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
GLAS Glass House Brands	N/A
HELP Cybin	17.94%
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
GLAS Glass House Brands	N/A
HELP Cybin	15.00%
NERV Minerva Neurosciences	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
GLAS Glass House Brands	N/A	93.80 million	N/A	N/A
HELP Cybin	50	75.61 million	64.27 million	N/A
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable

NERV, HELP, GLAS, and ACHV Headlines

Recent News About These Companies

Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average - Time to Sell?

September 4 at 3:01 AM | americanbankingnews.com

Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200-Day Moving Average - Here's What Happened

September 4 at 2:59 AM | marketbeat.com

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

August 28, 2026 | globenewswire.com

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200-Day Moving Average - Here's What Happened

August 22, 2026 | marketbeat.com

Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages

August 14, 2026 | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research

August 14, 2026 | marketbeat.com

HC Wainwright Has Bearish Estimate for NERV Q3 Earnings

August 12, 2026 | marketbeat.com

Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen

August 8, 2026 | marketbeat.com

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

August 7, 2026 | globenewswire.com

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

June 1, 2026 | globenewswire.com

Minerva Neurosciences Launches ATM Offering to Fund Trial

May 27, 2026 | tipranks.com

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

May 20, 2026 | zacks.com

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026 | globenewswire.com

Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | finanznachrichten.de

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

May 5, 2026 | globenewswire.com

Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69

April 28, 2026 | msn.com

Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation

April 16, 2026 | msn.com

Minerva launched with New Outperform at Citizens on schizophrenia candidate

April 15, 2026 | seekingalpha.com

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

April 6, 2026 | tipranks.com

Minerva Announces Leadership Transition

April 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NERV, HELP, GLAS, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$8.49 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Glass House Brands NYSE:GLAS

$8.89 +0.01 (+0.11%)

As of 09/4/2026 03:58 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Cybin NASDAQ:HELP

$12.22 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Minerva Neurosciences NASDAQ:NERV

$4.43 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, HELP, GLAS, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, HELP, GLAS, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, HELP, GLAS, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, HELP, GLAS, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Glass House Brands NYSE:GLAS

Cybin NASDAQ:HELP

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, HELP, GLAS, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, HELP, GLAS, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, HELP, GLAS, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NERV, HELP, GLAS, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Glass House Brands NYSE:GLAS

Cybin NASDAQ:HELP

Minerva Neurosciences NASDAQ:NERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools